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Introduction
In Taiwan, more than 85% of patients with end-stage
renal disease (ESRD) undergo maintenance hemodial-
ysis (HD). A well-functioning vascular access is neces-
sary for HD. There are 3 main types of long-term
vascular access for hemodialysis: (1) the cuffed and
tunneled double-lumen catheter; (2) the polytetraflu-
oroethylene (PTFE) arteriovenous graft (AVG); and
(3) the native arteriovenous fistula (AVF). Each of the
3 types of HD vascular access has its own advantages
and disadvantages.1 AVF is the preferred form of HD
vascular access on account of its lower risk of infection
and thrombosis.2 Since long-term technical survival is
best for native AVF, it accounts for more than 80% of
all the vascular accesses in HD patients in Taiwan.
With the use of Medicare data, about 17–25% of HD
patient hospitalizations in the United States result from
vascular access complications, at a cost of $1 billion
annually.3 Failure of dialysis access can result from
either inadequate blood flow on account of stenosis
of the venous outflow tract or complete occlusion
due to thrombosis.4 About 80–85% of arteriovenous
(AV) access failures come from AV access thromboses,
more than 80% of which result from AVF stenoses.4,5
Decreased access flow is associated with an increased
risk of access thrombosis. Access flow (Qa) < 500 mL/
min was demonstrated to be predictive of poorer unas-
sisted patency of native AVF by variable pump flow-
based Doppler ultrasound method in our previous
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study,6 which showed that the unassisted patency of
vascular access at 6 months was significantly poorer in
patients with Qa < 500 mL/min than in those with
Qa ≥ 500 mL/min (13.6% vs. 92.2%; p < 0.0001). In
addition to access flow, some mechanical factors influ-
ence AVF patency, such as the surgical skill, the punc-
ture technique, and the shear stress on the vascular
endothelia.
Medical Factors Contributing to
Malfunction of HD Vascular Access
As shown in Table 1, several medical factors have been
identified to be associated with vascular access steno-
sis in HD patients, including stasis, hypercoagulability,
endothelial cell injury, medications, and red cell mass.7
Stasis
Any cause of lower blood flow may predispose the vas-
cular access to stasis, which is an important component
of Virchow’s triad.
Hypotension
Intradialytic hypotension is connected with intravas-
cular blood volume, which is quite variable for each
patient.8 Regardless of the cause of hypotension, it
results in a reduction in access flow, making it more
susceptible to thrombosis.
Hypoalbuminemia
Hypoalbuminemia is related to a higher rate of throm-
bosis in PTFE AVG,9 especially in malnourished patients
as well as in cirrhotics.
Compression
Inappropriate compression of the vascular access after
HD may be associated with excessive direct pressure
applied by the patient or nursing staff on a vascular
access or by accident during sleep.
Hypercoagulable states
Antiphospholipid antibodies
Antiphospholipid antibodies include lupus anticoagu-
lant and anticardiolipin antibodies. ESRD patients in
general have been shown to have an elevated amount of
circulating antiphospholipid antibodies, and this amount
increases even more for those patients on HD.10
Lupus anticoagulant was shown to be associated with
access thrombosis,11 whereas anticardiolipin antibodies
were associated with recurrent access thrombosis.12
However, prospective studies are needed to determine
the association with vascular access thrombosis.
Hyperhomocysteinemia
The common risk factor for both deep venous throm-
bosis and atherosclerosis is homocysteine, which might
cause endothelial dysfunction, leading to impaired
thrombolytic capacity and vasodilation of vascular
J Chin Med Assoc • March 2009 • Vol 72 • No 3110
C.C. Lin, W.C. Yang
Table 1. Prognostic factors affecting patency of hemodialysis vascular access
Mechanical factors
Surgical skill
Technique of puncture vascular access
Shear stress on the vascular endothelia
Medical factors
Stasis: hypotension, hypoalbuminemia, compression
Hypercoagulable states: antiphospholipid antibodies, hyperhomocysteinemia, factor V leiden, lipoprotein(a)
Endothelial cell injury: preexisting intimal hyperplasia, TNF-α, oxidative stress, calcium phosphate deposition, activated platelets
Medications: ACEI (↑2° patency in AVF), CCB (↑1° patency in AVG), aspirin (↑2° patency in AVG), dipyridamole (↑AVG patency),
warfarin (↓1° patency in AVG)
Genotype polymorphisms with poor patency of AVF:
TGF-β1: high-producer haplotypes (+869/+915: TC/GG and TT/GG)
MTHFR: T allele of MTHFR C677T
HO-1: a longer length polymorphism with GT repeat number ≥ 30
Lower access flow: < 500 mL/min for AVF, < 600 mL/min for AVG
Others: higher RBC mass, less exercise, late referral, infection, DM, smoking
Physical therapy: far-infrared therapy
TNF-a = tumor necrosis factor-α; ACEI = angiotensin-converting enzyme inhibitor; ↑ = increased; 2° = secondary; AVF = arteriovenous fistula; CCB = calcium
channel blocker; 1° = primary; AVG = arteriovenous graft; ↓ = decreased; TGF-b1 = transforming growth factor-b1; MTHFR = methylene tetrahydrofolate reduc-
tase; HO-1 = heme oxygenase-1; RBC = red blood cell; DM = diabetes mellitus.
endothelium,13 and increased vascular smooth muscle
cell (VSMC) proliferation.14 Fukasawa et al showed
that the genotype polymorphism responsible for
hyperhomocysteinemia was associated with a higher
risk of AVF thrombosis.15 Some studies could not
demonstrate the relationship between hyperhomocys-
teinemia and vascular access thrombosis.16,17 A prospec-
tive study showed that hyperhomocysteinemia was
associated with a 4% increased risk of vascular access
failure.18 It was also shown that increased homocys-
teine levels could cause VSMC proliferation, while folic
acid supplementation inhibited this homocysteine-
induced proliferation.19 Treatment of hyperhomocys-
teinemia with oral folate has shown various results.
Some studies observed that there was no significant
effect of folate at doses of 1–5 mg/day, while others
showed a significant decrease.20 Bostom et al showed
that a daily 15 mg dose of folic acid could lower plasma
homocysteine levels in only one third of patients.21
The best factor predicting response to folate is the
baseline homocysteine levels, and higher doses of fo-
late of 30–60 mg/day were only more effective than
15 mg/day in patients with the methylene tetrahy-
drofolate reductase (MTHFR) 677TT genotype.22
More studies are needed to identify whether decreas-
ing homocysteine levels in HD patients can result in a
significant reduction of vascular access thrombosis.
Factor V leiden
A mutation at nucleotide position 1691 of the factor
V gene leads to the formation of factor V leiden,
which was associated with peripheral vascular graft
thrombosis due to hypercoagulability on account of
resistance to activated protein C.23 Patients with
homozygous mutation of the factor V gene have a
higher risk of developing vascular access thrombosis
than those with heterozygous mutation.
Lipoprotein(a)
Association of lipoprotein(a) with atherothrombotic
complications was reported in both the general and
ESRD populations but with equivocal results.24,25 It
was shown to be a risk factor for thrombosis in either
white or black patients, but the power in race-specific
analyses was inadequate in both studies.
Endothelial cell injury
Many factors lead to endothelial cell injury or dysfunc-
tion and they are listed as follows.
Preexisting intimal hyperplasia
Preexisting intimal hyperplasia is an important cause
of inadequate radial artery diameter, and histologic
examination revealed that this is quite common in
patients undergoing HD. Only diabetes and age are
risk factors for preexisting intimal hyperplasia. Intimal
hyperplasia of preexisting radial artery is also associated
with a lower frequency of 1-year patency of AVFs.26
Tumor necrosis factor-α (TNF-α)
Leukocytes release TNF-α, which could induce pro-
liferation of vascular smooth muscles leading to sub-
sequent intimal hyperplasia. The interaction between
PTFE AVGs and circulating peripheral blood mononu-
clear cells located upstream of the venous anastomosis
potentiates the release of TNF-α.27
Oxidative stress
Oxidative hyperactivity in the uremic status usually
leads to an increased amount of circulating and tissue
inflammatory molecules.28 Interaction with dialysis
membranes have also been reported as an important
cause leading to oxidative stress, resulting in an in-
creased expression of endothelin-1, which has been
associated with intimal hyperplasia and smooth muscle
cell vasoconstriction. Transforming growth factor-β
and platelet-derived growth factor have also been im-
plicated in intimal hyperplasia but seem to be clustered
at the venous end of the failed AV access.
Calcium phosphate deposition
Stenosis of AVFs were associated with calcium phos-
phate deposition, which is mainly in the form of calcium
apatite. Brushite, another calcium phosphate precipi-
tate, may be formed under acidic conditions and be
found in stenotic AVFs, but it was not present in non-
stenotic AVFs and normal veins (non-AVF).29 More
studies are needed to identify whether brushite is the
cause or a result of vascular access dysfunction.
Activated platelets
Injury to endothelial cells exposes the basement mem-
brane and extracellular matrix leading to activation of
platelets. It has been shown that higher levels of cir-
culating activated platelets are associated with shorter
survival of AV access. Inhibition of platelet activation
with aspirin and sulfinpyrazone has been shown to
prevent recurrent access thrombosis.30
Medications
The largest study evaluating the effects of specific
medications on AV access patency is the Dialysis Out-
comes and Practice Patterns Study (DOPPS).31 This
prospective, international study observed 900 AVFs
and 1,944 AVGs, and excluded failure of AV accesses
within 30 days due to technical failure. There were
J Chin Med Assoc • March 2009 • Vol 72 • No 3 111
Factors affecting vascular access and far infrared therapy
some informative results. The primary patency of AVFs
was not improved by any drug, and only angiotensin-
converting enzyme inhibitors improved secondary
patency. Calcium channel blockers improved primary
patency of AVGs, and aspirin improved secondary pa-
tency. Warfarin reduced primary graft patency, although
this may be due to deficiency of protein C or S. Another
study showed that dipyridamole alone was associated
with a significant risk reduction for AVG thrombosis,
while aspirin did not improve the risk of thrombosis.32
In addition, calcium channel blockers have been shown
to inhibit neointimal hyperplasia in AVGs.33
Red blood cell mass
According to the report by the Canadian Erythropoietin
Group, the incidence of vascular access thrombosis was
significantly increased in those patients receiving ery-
thropoietin.34 Churchill et al showed that erythropoi-
etin was not related to access thrombosis; however, their
study was not double-blinded.35 More double-blinded,
placebo-controlled, randomized trials are needed to de-
termine the role of erythropoietin in AV access patency.
Exercise
Leaf et al reported that an isometric exercise training
program could increase the diameter of the cephalic
vein, theoretically increasing the possibility of creation
of an AVF.36 More studies are needed to evaluate the
effect of exercise on patency rates.
Timely referral
Timely referral to nephrologists enables more precise
prediction of the appropriate timing for the placement
of a fistula or graft and the initiation of dialysis, which
could help HD patients avoid implantation of any tem-
porary catheter access. Not only would this avoid the
complications related to catheter placement, but it
would also reduce the frequency of AV access failure.37
Chesser and Baker reported that early referral to a
nephrologist was associated with a higher frequency
of patients starting HD on a functioning AVF and
lower overall mortality.38
Infection
About 50% of vascular access infections are caused by
Staphylococcus epidermidis, with Gram-negative organ-
isms accounting for approximately 23%.39 Staphylococcus
aureus accounts for about 20% of infections, and is
more likely than S. epidermidis to lead to bacteremia.
In addition, sources of bacterial seeding to AVGs may
come from sites other than dialysis punctures, such as
infective endocarditis, intravenous route used by drug
abuser or intra-abdominal abscess.
Cardiovascular risk factors
Certain demographic characteristics have been impli-
cated in AV access failure. Smoking, a risk factor for
atherosclerosis in general, is associated with both
early and late fistula failure. Diabetes has also consis-
tently been associated with access failure in prospec-
tive studies, possibly due to an increase in VSMC
proliferation.40
Genotype Polymorphisms and AVF
Malfunction
Transforming growth factor-b1 (TGF-b1)
The pathologic features of vascular access stenosis are
composed of intimal hyperplasia, VSMC proliferation
in the media with subsequent migration to intima,
and excessive accumulation of extracellular matrix,28
which are mediated by several growth factors such as
TGF-β1. The synthesis of TGF-β1 interindividually
differs due to the 2 single nucleotide polymorphisms
in the DNA sequence encoding the signal sequence
of the TGF-β1 protein, located at position +869
(codon 10, T > C, leucin > proline) and position +915
(codon 25, G > C, arginine > proline). Three different
cytokine-producer types are distinguished: high-
producer haplotypes are TC (codon 10)/GG (codon
25) and TT/GG; intermediate-producer haplotypes
are CC/GG, TC/GC, and TT/GC; and low-producer
haplotypes are CC/CC, CC/GC, TT/CC, and TC/
CC, respectively. AVF patency was significantly asso-
ciated with the TGF-β1 genotype; patencies were
62.4% and 81.2% after 12 months for TGF-β1 high
and intermediate producers, respectively.41
MTHFR
The MTHFR C677T polymorphism has been
reported to be closely related to plasma homocysteine
level. Percentages of patients who experienced AVF
malfunction were as follows: CC (12.6%), CT
(20.3%), and TT (31.8%). The number of those who
experienced obstruction was significantly larger with
TT than CC (p < 0.01). The odds ratio of genetic
polymorphisms predicting AVF malfunction is 1.77
for T allele-containing genotypes of MTHFR.15
Heme oxygenase-1 (HO-1)
HO-1 is another factor associated with higher risk of
developing some vascular diseases. HO plays a crucial
role in controlling intracellular heme levels by catalyz-
ing the rate-limiting step in the metabolism of heme.
HO cleaves the α-meso carbon bridge of heme, pro-
ducing equimolar quantities of carbon monoxide (CO),
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biliverdin, and free iron.42 Biliverdin is subsequently
metabolized to bilirubin by biliverdin reductase, and
free iron is promptly sequestered by ferritin. There
are 3 distinct isoenzymes of HO (HO-1, HO-2, HO-
3).43–45 HO-1 is an inducible 32-kDa protein that is
ubiquitously distributed and is located at chromosome
22q12.46 HO-1 induction stimulates cell cycle pro-
gression and proliferation in vascular endothelium,47
but inhibits the growth of VSMCs via the release of
CO. The mechanisms of CO-mediated apoptosis in
VSMCs include: (1) increase of p53 expression, which
is a proapoptotic protein; (2) release of cytochrome c
from the mitochondria;48 and (3) release of biliverdin
and bilirubin, which at high concentrations are known
inducers of apoptosis.49
Length polymorphisms in the dinucleotide
GT repeats
A (GT)n dinucleotide repeat with various length was
identified in the proximal promoter region.50 It func-
tions as a negative regulatory region and is located
between −198 and −258 of the human HO-1 pro-
moter. Individuals with shorter repeats (≤ 25) demon-
strate higher levels of HO-1, whereas individuals with
longer repeats (> 25) have lower levels of HO-1.51
HO-1 length polymorphisms and
cardiovascular diseases
Length polymorphisms of GT repeat in the promoter
region of the HO-1 gene vary between subjects and
correlate with disease activity. It was reported that a
longer length polymorphism of GT repeat (> 25 or
27 or 30) in HO-1 promoter was associated with sus-
ceptibility to the following conditions: restenosis and
increased vascular inflammation after percutaneous
transluminal angioplasty,52,53 coronary artery disease in
type 2 diabetic patients,54 Japanese patients with coro-
nary risk factors,55 and abdominal aortic aneurysms.56
Long GT repeat in HO-1 promoter and
poor AVF patency (Figure 1)
In our study,57 603 HD patients were enrolled; 178 had
history of AVF failure, while 425 did not. After correc-
tion for many factors (such as age, sex, HD duration,
underlying cause of ESRD), a significantly higher fre-
quency of AVF failure was still noted for the L/L and
L/S genotypes of HO-1, with a hazard ratio of 2.040
when compared with the S/S genotype. The propor-
tion of AVF failure increased from 20.3% for the S/S
genotype to 31.0% for the L/S genotype and 35.4% for
the L/L genotype. The unassisted patencies of AVF at
5 years decreased significantly from 83.8% to 75.1% and
69% in S/S, L/S and L/L genotypes, respectively.
Far-infrared Therapy Improves AVF
Patency Through Upregulation of 
HO-1 Expression (Figure 1)
Introduction
Infrared radiation is an invisible electromagnetic wave
with a longer wavelength than that of visible light.
According to the difference in wavelength, infrared
radiation can be divided into 3 categories: near-
infrared radiation (0.8–1.5 μm); middle-infrared radi-
ation (1.5–5.6 μm); and far-infrared (FIR) radiation
(5.6–1,000 μm).58 Infrared radiation transfers energy
that is perceived as heat by thermoreceptors in the
skin.59
Clinical applications
The application of FIR radiation includes food preser-
vation60 and health promotion.61,62 Animal studies have
demonstrated that FIR improves skin blood flow,63,64
leading to the use of FIR in the treatment of ischemic
lesions and necrosis of skin tissue due to trauma, dia-
betes mellitus and peripheral arterial-occlusive disease.
In addition, some studies indicate that FIR therapy
may improve endothelial function and reduce the 
frequency of some cardiovascular diseases, including
improving endothelial dysfunction in patients with
coronary risk factors, heart failure and arrhythmia.65–67
FIR therapy improves access flow and unassisted
patency of AVF in HD patients (Figure 1)
In our previous study,68 a total of 145 HD patients
were enrolled, with 73 in the control group and 72 in
the FIR group. The Qa1/Qa2 and Qa3/Qa4 were
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Figure 1. Summary of our study addressing the roles of heme
oxygenase-1 (HO-1) and far-infrared therapy in the regulation of
AVF function. The main results of our study are: (1) an association
of shorter dinucleotide GT repeat length polymorphisms (GT)n of
HO-1 gene promoter with higher patency of AVF in hemodialysis
patients; (2) a beneficial effect of far-infrared therapy on hemo-
dynamic parameters (including access flow, cardiac output) and
patency of vascular access in hemodialysis patients; and (3) a
stimulating effect of HO-1 expression by far-infrared therapy.
defined as the Qa measured at the beginning, at 40
minutes later in the HD session prior to the initiation,
and at the end of the study, respectively. The incre-
mental change in Qa in the single HD session with
FIR therapy was significantly higher than in that with-
out FIR therapy (13.2 ± 114.7 mL/min vs. −33.4 ±
132.3 mL/min). Compared with controls, patients
receiving FIR therapy for a year had: (1) lower inci-
dence (12.5% vs. 30.1%) of AVF malfunction; (2) higher
values of incremental change in access flow; and (3)
better unassisted patency of AVF (85.9% vs. 67.6%).
Mechanisms of FIR therapy
Our results indicate that both short-term and long-
term FIR can increase access flow. Moreover, there 
is an additive benefit of both short- and long-term
effects. The short-term thermal effect of FIR results
in vasodilatation and increasing Qa. According to the
report by Hartel et al, the temperature can be increased
up to 4°C in 10 mm depth of tissue.69 In addition,
infrared therapy may allow multiple energy transfers
as deep as 2–3 cm into subcutaneous tissue without
irritating or overheating the skin like unfiltered heat
radiation.69 The skin temperature steadily increased to
a plateau around 38–39°C during FIR treatment for
30–60 minutes as long as the distance between the
ceramic plate and the skin was more than 20 cm.63
In addition to the short-term thermal effect, the
increase in both Qa and fistula patency in this study
may result from the long-term (accumulated thermal
and non-thermal) effect of FIR therapy. In particular,
FIR may improve endothelial function, which was
observed not only in animal studies.63,64,66 but also in
one clinical study.65 Yu et al suggest that the beneficial
effect of FIR therapy on skin blood flow may be related
to L-arginine/nitric oxide pathway.63 Akasaki et al
found that repeated FIR therapy could upregulate
eNOS expression and augment angiogenesis in an
apolipoprotein E-deficient mouse model of unilateral
hind limb ischemia.64 Moreover, Ikeda et al reported
that 4 weeks of sauna therapy significantly increased
serum nitrate concentrations as well as the expression
of mRNA and protein of eNOS in the aortas of TO-2
hamsters.66 In addition, Imamura et al showed that 2
weeks of repeated sauna therapy significantly improved
vascular endothelial function, resulting in an increase
in flow-mediated endothelium-dependent dilatation
of the brachial artery from 4% to 5.8% in patients with
coronary risk factors.65
Our recent study also showed that FIR induced
expression of HO-1 via stimulating NF-E2-related
factor-2 (Nrf2)-dependent promoter activity, with the
maximal time-course effect on the expression of HO-1
and Nrf2 both at 6 hours.70 Tumor necrosis factor-α
(TNF-α)-induced expression of E-selectin, vascular
cell adhesion molecule-1 (VCAM-1), and intercellu-
lar cell adhesion molecule-1 (ICAM-1) were maxi-
mally suppressed by FIR therapy at 4, 6 and 24 hours,
respectively. Higher expression of HO-1 may explain
the antiproliferative and anti-inflammatory effect of
FIR therapy.
Besides activating expression of eNOS and HO-1,
inhibiting neointimal hyperplasia and decreasing
oxidative stress are 2 other non-thermal effects of FIR
therapy. Kipshidze et al found that nonablative infrared
laser therapy inhibited neointimal hyperplasia after
PTCA in cholesterol-fed rabbits for up to 60 days due
to suppression of the growth of VSMCs.71 In addition,
Masuda et al72 showed that patients receiving FIR dry
sauna for 45 minutes a day for 2 weeks had lower systolic
blood pressure and urinary levels of 8-epi-prostaglandin
F2α, which is a chemically stable product of lipid per-
oxidation, and the level has been suggested to be a
reliable marker of oxidative stress in vivo.73
In conclusion, many factors may affect the progno-
sis of vascular access. FIR therapy, a noninvasive and
convenient therapeutic modality, can improve Qa,
inflammatory status and survival of the AVF in HD
patients through both its thermal and the above-
mentioned non-thermal (anti-inflammatory) effects
by upregulating Nrf2-dependent HO-1 expression,
leading to the inhibition of E-selectin, VCAM-1 and
ICAM-1 expression.
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